Despite being in the news regularly, few people in the industry truly understand the nuances of the 340B Drug Pricing Program. But this program is becoming critical to the economics of stakeholders across the healthcare ecosystem from drug manufacturers and providers to health systems and pharmacy benefit manager (PBM) owned contract pharmacies. To help dissect […]| Hospitalogy
The Source Roundup: October 2024 Edition| The Source on HealthCare Price and Competition
Johnson & Johnson| www.hrsa.gov